The Novartis-backed eye disease treatment developer, which filed to go public earlier this month, has now raised almost $78m from two equity rounds.
France-based biotechnology company GenSight Biologics raised $36m in series B funding today and added several backers to an investor base already including pharmaceutical firm Novartis.
Fidelity Management & Research Company, Jennison Associates, Sphera Global HealthCare Fund, Perceptive Advisors and HealthCap joined GenSight’s series A investors in the round.
GenSight raised $41.8m in 2013 from Novartis Venture Fund, a corporate venturing subsidiary of Novartis, Abingworth, Versant Ventures and Index Ventures.
Founded in 2011, GenSight is working on treatments for eye…
